Momekort Zur Anwendung Bei Erwachsenen (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors in the cells lining the nasal passages. This interaction modifies gene transcription, leading to decreased production of inflammatory cytokines and chemokines, and suppresses activation of immune cells. The result is reduced swelling, mucus production and overall nasal inflammation.

The exact dosing regimen for Momekort is determined by the prescribing healthcare professional. The prescriber will specify the number of sprays per nostril, the frequency per day, and the overall duration of therapy based on the severity of the condition, patient response and any other relevant clinical factors.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. Use is only recommended if the potential benefit to the mother outweighs any possible risk to the fetus or infant. The decision should be made by a qualified healthcare provider after a thorough risk‑benefit assessment.

To place an order, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Momekort contains mometasone furoate, a second‑generation corticosteroid with high receptor affinity and low systemic bioavailability. Compared with older agents such as beclomethasone or fluticasone, it offers potent anti‑inflammatory activity with a favorable safety profile, though individual response and prescriber preference ultimately guide therapy choice.

Store the nasal spray at room temperature, below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keep the device out of reach of children and do not freeze the product.

Before use, gently blow the nose. Tilt the head slightly forward, insert the spray tip into one nostril while closing the other nostril with a finger. Press the pump to deliver the prescribed number of sprays, then repeat in the other nostril if directed. Avoid blowing the nose immediately after dosing.

Rare but serious adverse events may include severe nosebleeds, vision changes, or signs of systemic corticosteroid exposure such as adrenal suppression. If a patient experiences unusual bleeding, visual disturbances, or symptoms suggestive of hormonal imbalance, they should seek medical attention promptly.

Momekort is contraindicated in individuals with known hypersensitivity to mometasone furoate or any excipients in the formulation. It should also be avoided in patients with active, untreated nasal infections, recent nasal surgery, or those for whom systemic corticosteroid exposure is undesirable, unless specifically directed by a physician.